




RealRate

# PHARMACEUTICAL 2012

Arrowhead Pharmaceuticals INC  
Rank 191 of 196



The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 0.0072% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.012%, being 234% points below the market average of 234%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 9,861             |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 2,582             |
| Liabilities, Non-Current                    | 742               |
| Other Assets                                | 6,002             |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 34,099            |
| Other Liabilities                           | 0                 |
| Other Net Income                            | -35,415           |
| Other Revenues                              | 3,992             |
| Property and Equipment                      | 25                |
| Research and Development                    | 40,429            |
| Selling, General and Administrative Expense | 25,591            |

| Output Variable             | Value in 1000 USD |
|-----------------------------|-------------------|
| Assets                      | 15,889            |
| Liabilities                 | 3,324             |
| Expenses                    | 100,119           |
| Revenues                    | 3,992             |
| Stockholders Equity         | 12,564            |
| Net Income                  | -131,542          |
| Comprehensive Net Income    | -131,542          |
| BaseVar                     | 79,370            |
| ECR before LimitedLiability | -1,084%           |
| Economic Capital Ratio      | 0.012%            |